LEADER 03851nam  2200805z- 450 
001 9910639987503321
005 20231214133546.0
010   $a3-0365-6090-4
035   $a(CKB)5470000001633479
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/95822
035   $a(EXLCZ)995470000001633479
100   $a20202301d2022      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCOVID-19 and Gastrointestinal Disease: Current Insights and Future Management
210   $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022
215   $a1 electronic resource (184 p.)
311   $a3-0365-6089-0 
330   $aCOVID-19 is the most prominent and rapidly evolving public health concern in the world currently. The gastrointestinal manifestations of COVID-19 are increasingly being recognized. SARS-CoV-2 infection has been associated with the occurrence of nausea, vomiting, and diarrhea. SARS-CoV-2 has also been causing pancreatic and hepatic injury. Emerging data have shown that COVID-19 patients continue to shed the virus into their stools, even when patients test negative for COVID-19 in pulmonary secretions. However, the epidemiology, pathogenesis, and treatment of SARS-CoV-2-related gastrointestinal manifestations are poorly understood. The pandemic has also had a significant impact on gastroenterologists, endoscopists, and other ancillary staff. Moreover, in the past, systematic respiratory virus syndrome (SARS) was shown to be transmitted by endoscopes, which is a big concern with COVID-19, as it shares many pathological features with SARS. The deferral of elective endoscopic procedures has negatively affected gastroenterologists. This Special Issue focuses on the current situation of this pandemic. It aims to provide insight into the gastrointestinal manifestations of COVID-19 and its effects on endoscopic procedures. I believe that this issue will be beneficial not only for gastroenterologists but also other healthcare workers around the world to recognize the often-ignored clinical gastrointestinal manifestations of COVID-19.
517   $aCOVID-19 and Gastrointestinal Disease
606   $aMedicine$2bicssc
610   $aCOVID-19
610   $aliver
610   $anon-alcoholic steatohepatitis
610   $atransient elastography
610   $amortality
610   $aliver disease
610   $aclinical manifestations
610   $aSARS-CoV-2
610   $agastroenterology
610   $ahepatology
610   $aendoscopy
610   $adelivery of healthcare
610   $aacute mesenteric ischemia
610   $athromboemboembolism
610   $aendothelitis
610   $acytokines
610   $ahypercoagulability
610   $ainflammatory bowel disease
610   $agastrointestinal manifestations
610   $aabdominal pain
610   $adyspnea
610   $aclinical course
610   $aupper gastrointestinal bleeding
610   $apandemic
610   $aoutcomes
610   $aanxiety
610   $adepression
610   $amedication adherence
610   $aseverity of COVID-19
610   $ahospitalized patients
610   $arisk factors
610   $aSARS-CoV-2 infection
610   $agut dysbiosis
610   $amicrobiota
610   $agastrointestinal disorders
610   $aintestinal inflammation
610   $aACE2 dysregulation
610   $agut microbiota
610   $aenteric infection
615  7$aMedicine
700   $aGoyal$b Hemant$4edt$01279880
702   $aGoyal$b Hemant$4oth
906   $aBOOK
912   $a9910639987503321
996   $aCOVID-19 and Gastrointestinal Disease: Current Insights and Future Management$93016105
997   $aUNINA